Please wait while the formulary information is being retrieved.
Drug overview for LASTACAFT (alcaftadine):
Generic name: ALCAFTADINE (al-KAF-ta-deen)
Drug class: Ophthalmic Antiallergic Agents
Therapeutic class: Ophthalmic Agents
Alcaftadine is a histamine H1-receptor antagonist.
No enhanced Uses information available for this drug.
Generic name: ALCAFTADINE (al-KAF-ta-deen)
Drug class: Ophthalmic Antiallergic Agents
Therapeutic class: Ophthalmic Agents
Alcaftadine is a histamine H1-receptor antagonist.
No enhanced Uses information available for this drug.
DRUG IMAGES
No Image Available
The following indications for LASTACAFT (alcaftadine) have been approved by the FDA:
Indications:
Allergic conjunctivitis
Professional Synonyms:
Allergy eye itch
Atopic conjunctivitis
Itchy eyes due to allergies
Ocular itching due to allergies
Indications:
Allergic conjunctivitis
Professional Synonyms:
Allergy eye itch
Atopic conjunctivitis
Itchy eyes due to allergies
Ocular itching due to allergies
The following dosing information is available for LASTACAFT (alcaftadine):
No enhanced Dosing information available for this drug.
Alcaftadine is applied topically to the eye as an ophthalmic solution. The ophthalmic solution is for topical ophthalmic use only. Care should be taken to avoid contamination of the solution container.
Alcaftadine ophthalmic solution contains benzalkonium chloride, which may be absorbed by some soft contact lenses. Patients should be advised to remove their contact lenses prior to administration of each dose of alcaftadine ophthalmic solution. Patients whose eyes are not red may reinsert soft contact lenses after 10 minutes following administration of the ophthalmic solution.
Alcaftadine ophthalmic solution is for topical ophthalmic use only. The ophthalmic solution should not be instilled while the patient is wearing contact lenses. Patients should be advised not to wear contact lenses if their eyes are red.
The ophthalmic solution should not be used to treat contact lens-related irritation. (See Dosage and Administration: Administration.)
Alcaftadine ophthalmic solution contains benzalkonium chloride, which may be absorbed by some soft contact lenses. Patients should be advised to remove their contact lenses prior to administration of each dose of alcaftadine ophthalmic solution. Patients whose eyes are not red may reinsert soft contact lenses after 10 minutes following administration of the ophthalmic solution.
Alcaftadine ophthalmic solution is for topical ophthalmic use only. The ophthalmic solution should not be instilled while the patient is wearing contact lenses. Patients should be advised not to wear contact lenses if their eyes are red.
The ophthalmic solution should not be used to treat contact lens-related irritation. (See Dosage and Administration: Administration.)
| DRUG LABEL | DOSING TYPE | DOSING INSTRUCTIONS |
|---|---|---|
| LASTACAFT ONCE DAILY 0.25% DRP | Maintenance | Adults instill 1 drop into affected eye(s) by ophthalmic route once daily |
| DRUG LABEL | DOSING TYPE | DOSING INSTRUCTIONS |
|---|---|---|
| ALCAFTADINE 0.25% EYE DROP | Maintenance | Adults instill 1 drop into affected eye(s) by ophthalmic route once daily |
The following drug interaction information is available for LASTACAFT (alcaftadine):
There are 0 contraindications.
There are 0 severe interactions.
There are 0 moderate interactions.
The following contraindication information is available for LASTACAFT (alcaftadine):
Drug contraindication overview.
The manufacturer states that there are no known contraindications to the use of alcaftadine.
The manufacturer states that there are no known contraindications to the use of alcaftadine.
There are 0 contraindications.
There are 0 severe contraindications.
There are 1 moderate contraindications.
Clinically significant contraindication, where the condition can be managed or treated before the drug may be given safely.
| Moderate List |
|---|
| No disease contraindications |
The following adverse reaction information is available for LASTACAFT (alcaftadine):
Adverse reaction overview.
The most common adverse ocular effects (reported in less than 4% of eyes treated with alcaftadine ophthalmic solution) include irritation, burning, and/or stinging upon instillation; redness; and pruritus. Common nonocular adverse effects (reported in less than 3% of patients receiving the drug) include nasopharyngitis, headache, and influenza.
The most common adverse ocular effects (reported in less than 4% of eyes treated with alcaftadine ophthalmic solution) include irritation, burning, and/or stinging upon instillation; redness; and pruritus. Common nonocular adverse effects (reported in less than 3% of patients receiving the drug) include nasopharyngitis, headache, and influenza.
There are 0 severe adverse reactions.
There are 14 less severe adverse reactions.
| More Frequent | Less Frequent |
|---|---|
|
Ocular irritation |
Headache disorder Ocular itching Ocular redness Pharyngitis |
| Rare/Very Rare |
|---|
|
Allergic dermatitis Blurred vision Drowsy Eye tearing Eyelid edema Eyelid erythema Facial edema Ocular discharge Periorbital edema |
The following precautions are available for LASTACAFT (alcaftadine):
Safety and efficacy of alcaftadine ophthalmic solution have not been established in children younger than 2 years of age. Pediatric patients 10 years of age or older were included in controlled clinical trials evaluating efficacy and safety of alcaftadine ophthalmic solution, and pediatric patients 3 years of age or older were included in environmental studies establishing safety of the drug. Efficacy of the drug in children 2-9 years of age was extrapolated from demonstrated efficacy in older children and adults.
Contraindicated
Severe Precaution
Management or Monitoring Precaution
Contraindicated
| None |
Severe Precaution
| None |
Management or Monitoring Precaution
| None |
Category B. (See Users Guide.)
It is not known whether alcaftadine is distributed into milk following topical application to the eye. Because many drugs are distributed into milk, caution should be exercised when alcaftadine is used in nursing women.
No overall differences in safety or efficacy were observed between geriatric patients and younger patients.
The following prioritized warning is available for LASTACAFT (alcaftadine):
No warning message for this drug.
No warning message for this drug.
The following icd codes are available for LASTACAFT (alcaftadine)'s list of indications:
| Allergic conjunctivitis | |
| H10.1 | Acute atopic conjunctivitis |
| H10.10 | Acute atopic conjunctivitis, unspecified eye |
| H10.11 | Acute atopic conjunctivitis, right eye |
| H10.12 | Acute atopic conjunctivitis, left eye |
| H10.13 | Acute atopic conjunctivitis, bilateral |
| H10.44 | Vernal conjunctivitis |
| H10.45 | Other chronic allergic conjunctivitis |
| H16.26 | Vernal keratoconjunctivitis, with limbar and corneal involvement |
| H16.261 | Vernal keratoconjunctivitis, with limbar and corneal involvement, right eye |
| H16.262 | Vernal keratoconjunctivitis, with limbar and corneal involvement, left eye |
| H16.263 | Vernal keratoconjunctivitis, with limbar and corneal involvement, bilateral |
| H16.269 | Vernal keratoconjunctivitis, with limbar and corneal involvement, unspecified eye |
Formulary Reference Tool